Provention Bio Inc. (PRVB) Misses Q1 EPS by 6c

Provention Bio Inc. (NASDAQ: PRVB) reported Q1 EPS of ($0.52), $0.06 worse than the analyst estimate of ($0.46).

"The first quarter of 2021 marked another quarter of strong execution across Provention Bio as we continue to advance our portfolio of autoimmunology therapeutic candidates focused on intercepting and preventing life-threatening and life-impacting diseases," stated Ashleigh Palmer, CEO of Provention Bio. Mr. Palmer continued, "Our near-term focus is appropriately concentrated on the BLA filing for teplizumab and the upcoming FDA Advisory Committee meeting on May 27. We believe this Advisory Committee meeting's agenda will include examination of type 1 diabetes unmet need and the safety and efficacy of teplizumab from the TN-10 trial supported by data from other historic studies in newly diagnosed patients. Also, we concurrently continue to make great progress advancing all of our other autoimmunology pipeline candidates, which positions us very well for numerous important data catalysts over the course of the next 12 to 24 months."

For earnings history and earnings-related data on Provention Bio Inc. (PRVB) click here.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• Galmed's Aramchol shows added cell death in prostate cancer study
• MiniMed ships its Flex pump with Abbott's Instinct sensor in the U.S.